Novo Nordisk’s Sickle Cell Drug Delivers as Buyback Program Advances
Novo Nordisk’s oral sickle cell drug etavopivat met Phase 3 goals, cutting painful crises by 27%. The success…
European Lithium’s Greenland Rare Earths Project Enters New Phase with Leadership Shift
European Lithium’s stake in Critical Metals Corp surges as Greenland approves full project control, appointing a local CEO…
Novo Nordisk’s Buyback and Breakthrough Paint a Complex Picture
Novo Nordisk executes major share buybacks and announces positive Phase 3 results for sickle cell drug etavopivat, pressuring…
Novo Nordisk’s Clinical Win and Competitive Crossroads
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…
Novo Nordisk’s Clinical Win and Competitive Crossroads
Novo Nordisk’s etavopivat meets Phase 3 goals in sickle cell disease, a bright spot as shares fall 23%…